Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why

Posted by Francis Steltz on May 31st, 2026

Anika Therapeutics Inc. (NASDAQ:ANIK – Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $12.00 and traded as high as $15.79. Anika Therapeutics shares last traded at $14.53, with a volume of 99,745 shares changing hands.

Analysts Set New Price Targets

A number of brokerages have recently commented on ANIK. Barrington Research increased their price objective on Anika Therapeutics from $16.00 to $17.00 and gave the company an “outperform” rating in a report on Friday, February 27th. Wall Street Zen lowered Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Anika Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Read Our Latest Research Report on Anika Therapeutics

Anika Therapeutics Trading Down 2.5%

The stock has a market cap of $193.39 million, a price-to-earnings ratio of -18.39 and a beta of 0.16. The stock has a fifty day simple moving average of $14.83 and a 200-day simple moving average of $12.00.

Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.34. The firm had revenue of $29.61 million for the quarter, compared to analyst estimates of $28.14 million. Anika Therapeutics had a negative return on equity of 5.90% and a negative net margin of 9.52%. Sell-side analysts forecast that Anika Therapeutics Inc. will post -0.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director John B. Henneman III acquired 5,000 shares of Anika Therapeutics stock in a transaction on Friday, May 1st. The stock was bought at an average price of $14.66 per share, for a total transaction of $73,300.00. Following the transaction, the director owned 54,871 shares of the company’s stock, valued at $804,408.86. The trade was a 10.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephen D. Griffin acquired 12,200 shares of Anika Therapeutics stock in a transaction on Thursday, April 30th. The stock was purchased at an average price of $12.29 per share, with a total value of $149,938.00. Following the transaction, the chief executive officer directly owned 36,163 shares in the company, valued at approximately $444,443.27. This trade represents a 50.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 12.08% of the stock is currently owned by company insiders.

Institutional Trading of Anika Therapeutics

Hedge funds have recently modified their holdings of the company. Quarry LP bought a new stake in shares of Anika Therapeutics in the 3rd quarter worth approximately $71,000. CWM LLC lifted its position in shares of Anika Therapeutics by 14.5% in the 4th quarter. CWM LLC now owns 8,537 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 1,080 shares during the period. Ieq Capital LLC bought a new stake in shares of Anika Therapeutics in the 4th quarter worth approximately $97,000. Occudo Quantitative Strategies LP bought a new stake in shares of Anika Therapeutics in the 3rd quarter worth approximately $95,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Anika Therapeutics in the 3rd quarter worth approximately $107,000. Institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Company Profile

(Get Free Report)

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.